journal article·2015-11-10

Interactions of Apolipoproteins AI, AII, B and HDL, LDL, VLDL with Polyurethane and Polyurethane-PEO Surfaces

R.M. Cornelius, J. Macri, K.M. Cornelius, J.L. Brash

Langmuir· Volume 31· Issue 44
Publisher page

Abstract

The lipoproteins (HDL, LDL, VLDL) are important components of blood present in high concentration. Surprisingly, their role in blood-biomaterial interactions has been largely ignored. In previous work apolipoprotein AI (the main protein component of HDL) was identified as a major constituent of protein layers adsorbed from plasma to biomaterials having a wide range of surface properties, and quantitative data on the adsorption of apo AI to a biomedical grade polyurethane were reported. In the present communication quantitative data on the adsorption of apo AI, apo AII and apoB (the latter being a constituent of LDL and VLDL), as well as the lipoprotein particles themselves (HDL, LDL, VLDL), to a biomedical segmented polyurethane (PU) with and without an additive containing poly(ethylene oxide) (material referred to as PEO) are reported. Using radiolabeled apo AI, apo AII, and apoB, adsorption levels on PU from buffer at a protein concentration of 50 μg/mL were found to be 0.34, 0.40, and 0.14 μg/cm(2) (12, 23, and 0.25 nmol/cm(2)) respectively. Adsorption to the PEO surface was <0.02 μg/cm(2) for all three apolipoproteins demonstrating the strong protein resistance of this material. In contrast to the apolipoproteins, significant amounts of the lipoproteins were found to adsorb to the PEO as well as to the PU surface. X-ray photoelectron spectra, following exposure of the surfaces to the lipoproteins, showed a strong phosphorus signal, confirming that adsorption had occurred. It therefore appears that a PEO-containing surface that is resistant to apolipoproteins may be less resistant to the corresponding lipoproteins.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Muscle metabolism and nutrition · Diabetes, Cardiovascular Risks, and Lipoproteins · Blood properties and coagulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering ‡Department of Pathology & Molecular Medicine §Department of Biology ∥School of Biomedical Engineering McMaster University Hamilton, Ontario Canada

Funding

Natural Sciences and Engineering Research Council of Canada

References (51)

Show source-provided references
1. 10.1039/C4TB00881B10.1039/C4TB00881B ↗
2. 10.1038/nrg248110.1038/nrg2481 ↗
3. 10.1016/S0142-9612(02)00083-210.1016/S0142-9612(02)00083-2 ↗
4. 10.1002/jbm.a.3316910.1002/jbm.a.33169 ↗
5. Scanu A. · Clin. Physiol. Biochem · 1984 · 2 · 111
6. 10.1016/0006-291X(78)91614-510.1016/0006-291X(78)91614-5 ↗
7. 10.1016/j.cca.2007.10.02810.1016/j.cca.2007.10.028 ↗
8. 10.1074/jbc.M109.09843410.1074/jbc.M109.098434 ↗
9. 10.1016/j.jmb.2009.02.03610.1016/j.jmb.2009.02.036 ↗
10. 10.1073/pnas.69.5.130410.1073/pnas.69.5.1304 ↗
11. 10.3109/07853890.2011.57349810.3109/07853890.2011.573498 ↗
12. Edelstein C. · J. Biol. Chem. · 1982 · 257 · 718910.1016/S0021-9258(18)34555-1 ↗
13. 10.1074/jbc.M111.29107010.1074/jbc.M111.291070 ↗
14. Johs A. · J. Biol. Chem. · 2006 · 281 · 1973210.1074/jbc.M601688200 ↗
15. 10.1073/pnas.060221310310.1073/pnas.0602213103 ↗
16. 10.1097/HCO.0b013e328304380610.1097/HCO.0b013e3283043806 ↗
17. 10.1161/01.ATV.0000194291.94269.5a10.1161/01.ATV.0000194291.94269.5a ↗
18. 10.1016/S0140-6736(01)07098-210.1016/S0140-6736(01)07098-2 ↗
19. 10.1016/S0140-6736(04)17018-910.1016/S0140-6736(04)17018-9 ↗
20. 10.1016/j.accreview.2005.05.03210.1016/j.accreview.2005.05.032 ↗
21. 10.1046/j.1365-2796.2003.01276.x10.1046/j.1365-2796.2003.01276.x ↗
22. 10.1002/jbm.a.3154810.1002/jbm.a.31548 ↗
23. 10.1002/jbm.a.3155410.1002/jbm.a.31554 ↗
24. Knight L. C. · Thromb Haemost · 1981 · 46 · 59310.1055/s-0038-1653425 ↗
25. Pierce Chemical Company.IODO-GEN Iodination Reagent, 1993.
26. Regoeczi E. · 1984 · 1
27. Counsell R. E. · J. Nucl. Med. · 1980 · 21 · 852
28. 10.1016/j.colsurfb.2003.09.00410.1016/j.colsurfb.2003.09.004 ↗
29. 10.1097/00002480-200205000-0001710.1097/00002480-200205000-00017 ↗
30. 10.1016/S0142-9612(97)00242-110.1016/S0142-9612(97)00242-1 ↗
31. 10.1002/jbm.a.3097710.1002/jbm.a.30977 ↗
32. 10.1006/jcis.1996.004510.1006/jcis.1996.0045 ↗
33. 10.1073/pnas.050687710310.1073/pnas.0506877103 ↗
34. 10.1021/bi401080k10.1021/bi401080k ↗
35. 10.1016/0005-2760(88)90195-610.1016/0005-2760(88)90195-6 ↗
36. 10.1002/jbm.82029030610.1002/jbm.820290306 ↗
37. 10.1016/j.biomaterials.2005.12.02510.1016/j.biomaterials.2005.12.025 ↗
38. 10.1371/journal.pone.012283610.1371/journal.pone.0122836 ↗
39. 10.1002/jbm.82021060210.1002/jbm.820210602 ↗
40. 10.1046/j.1525-1594.2000.06476.x10.1046/j.1525-1594.2000.06476.x ↗
41. 10.1093/ndt/gfn12710.1093/ndt/gfn127 ↗
42. 10.1002/mabi.20110007110.1002/mabi.201100071 ↗
43. 10.1021/la401464a10.1021/la401464a ↗
44. 10.1039/C4RA16700G10.1039/C4RA16700G ↗
45. 10.1016/j.molmed.2010.10.00610.1016/j.molmed.2010.10.006 ↗
46. Kontush A. · 2015 · 224 · 3
47. 10.1080/0003271100379009810.1080/00032711003790098 ↗
48. 10.1021/ja402126t10.1021/ja402126t ↗
49. 10.1016/j.biomaterials.2013.12.02210.1016/j.biomaterials.2013.12.022 ↗
50. 10.1021/la304886r10.1021/la304886r ↗
51. Vanags L. · Hypertension · 2014 · 63 · E172